Barclays lowered the firm’s price target on Humana (HUM) to $245 from $315 and keeps an Equal Weight rating on the shares. The firm says that to diversify its contracts, Humana is promoting new growth into H7617, a 4.5-star contract that currently holds 11,000 Medicare Advantage members and has nearly identical benefits to H5216.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Humana’s Strategic Initiatives to Enhance Medicare Advantage Performance and Financial Margins
- Evercore says Humana’s preliminary MA Star ratings inline with expectations
- Humana Projects Strong 2025 Earnings Amidst Star Ratings Challenge
- Humana affirms 2025 adjusted EPS outlook $17.00, consensus $17.03
- Humana rallies 6% to $261.71 after star ratings disclosure, affirming outlook